Suito

Suito is a combination of two non-nutritive, high-intensity artificial sweeteners used as a sugar substitute in foods, beverages, oral pharmaceutical formulations (e.g., syrups, chewable tablets, powders), and tabletop sweetener products.

Established Uses

• As a sugar substitute for individuals managing diabetes mellitus who need to reduce dietary sugar/carbohydrate intake.
• As a sugar substitute for individuals reducing overall caloric intake as part of a weight-management plan.
• As a flavoring/sweetening agent in sugar-free or reduced-sugar pharmaceutical oral formulations, to improve palatability without adding calories or affecting blood glucose.

General Dietary Use

Suito is also widely used in commercial food and beverage products (soft drinks, tabletop sweeteners, baked goods, dairy products) as a general-purpose sugar replacement for the general population, not limited to any specific medical condition.

Suito is not a treatment for diabetes itself; it does not replace prescribed antidiabetic therapy.

Sucralose + Acesulfame Potassium contains two components:

• Sucralose - a chlorinated derivative of sucrose, approximately 600 times sweeter than table sugar, essentially non-caloric.
• Acesulfame Potassium (Acesulfame-K) - a potassium salt of a synthetic organic acid, approximately 200 times sweeter than table sugar, non-caloric.

The two components are frequently combined because they produce a synergistic sweetness (allowing a lower total amount of sweetener to be used) and because Acesulfame Potassium's fast onset complements Sucralose's more sustained, sugar-like taste profile.

Suito is a combination sweetening agent composed of two chemically distinct, non-nutritive artificial sweeteners: sucralose and acesulfame potassium. Neither component is significantly metabolized by the body for energy, so Suito contributes negligible or no calories compared to sucrose (table sugar).

Both components of Suito are heat-stable to varying degrees, are excreted largely unchanged, and are widely used together in the food, beverage, and pharmaceutical industries as a sugar substitute.

Suito belongs to the category of non-nutritive, high-intensity artificial sweeteners (sugar substitutes). It is classified as a food additive/excipient rather than a therapeutic drug, and is generally recognized as safe (GRAS) by regulatory authorities when used within established intake limits.

Mechanism of Sweetness

Both components of Sucralose + Acesulfame Potassium act by binding to and activating the sweet taste receptors (T1R2/T1R3) on the tongue, producing an intense sweet taste sensation without contributing meaningful calories or significantly affecting blood glucose or insulin levels.

Pharmacokinetics

• Sucralose: Poorly absorbed from the gastrointestinal tract (approximately 11-27% absorbed); the absorbed fraction is not metabolized and is excreted largely unchanged in urine, while the unabsorbed fraction is excreted in feces.
• Acesulfame Potassium: Rapidly absorbed from the gastrointestinal tract, not metabolized in the body, and excreted essentially unchanged in urine within hours.

Because Sucralose + Acesulfame Potassium is not metabolized to a clinically significant extent, it does not raise blood glucose levels and has a minimal caloric contribution, which is the pharmacological basis for its use as a sugar substitute.

Suito is added to or already present in foods, beverages, or oral pharmaceutical formulations and is taken by mouth as part of the product it sweetens. No special administration technique is required.

Suito has not been shown to have clinically significant pharmacokinetic drug interactions, as neither component undergoes meaningful metabolism via cytochrome P450 enzymes or other major drug-metabolizing pathways.

Points of Clinical Relevance

• Antidiabetic therapy: Suito does not itself lower or raise blood glucose, so it does not directly interact with insulin or oral antidiabetic medications; however, it should not be assumed to replace prescribed antidiabetic treatment, and patients should continue blood glucose monitoring and medication as directed by their physician.
• Other sweeteners/sugar alcohols: Combining Suito with large amounts of other sugar substitutes in the diet may increase total gastrointestinal load and the likelihood of GI discomfort (see Side Effects).

Suito is generally well tolerated within established acceptable daily intake limits. Reported side effects are uncommon and typically mild.

• Gastrointestinal discomfort, bloating, or flatulence, particularly with high intake of Suito or other sugar substitutes.
• Headache (rarely reported with high intake).
• Rare hypersensitivity reactions (e.g., skin rash, itching) in sensitive individuals.

Serious adverse effects from Suito at typical dietary or pharmaceutical excipient levels are rare.

Suito is generally considered acceptable for use during pregnancy and lactation when intake of each component remains within the established acceptable daily intake (ADI) limits, based on currently available safety data. However, as with any substance consumed during pregnancy or breastfeeding, Suito should be used only if clearly needed and in moderation, and pregnant or breastfeeding individuals should consult a physician regarding their overall dietary sweetener intake, particularly if consuming Suito from multiple combined dietary sources.

Suito is generally recognized as safe when used within the established acceptable daily intake (ADI) limits for each component. The following precautions should be observed:

• Avoid excessive intake of Suito beyond the recommended ADI when combined intake from all dietary sources (food, beverages, tabletop sweetener, and pharmaceutical products) is considered.
• Some individuals may experience gastrointestinal discomfort or bloating with high intake of Suito or other sugar substitutes; reducing intake typically resolves this.
• Suito does not replace medical management of diabetes; blood glucose monitoring and prescribed antidiabetic therapy should continue as directed by a physician.
• Heat stability differs between the two components of Suito: acesulfame potassium is heat-stable, while the heat stability of sucralose can vary by formulation and cooking conditions; product labeling should be checked before using Suito-containing products in cooking or baking.
• Scientific understanding of the long-term metabolic effects of artificial sweeteners, including Suito, continues to evolve; individuals with specific health concerns should discuss overall sweetener use with their physician.
• Unlike aspartame, Suito is not a concern for individuals with phenylketonuria (PKU), as neither sucralose nor acesulfame potassium contains phenylalanine.

Consuming Suito in amounts significantly exceeding the established acceptable daily intake is unlikely to cause serious harm but may increase the likelihood of gastrointestinal symptoms such as bloating, gas, or diarrhea. If a very large, unintended intake of Suito occurs, or if any concerning symptoms develop, seek medical attention or contact a poison control center for guidance; do not attempt unsupervised specific home treatment beyond general supportive measures.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Diabetes Mellitus

Suito is commonly used by individuals with diabetes as a sugar substitute; it does not directly affect blood glucose, but does not replace prescribed antidiabetic therapy or glucose monitoring.

Renal Impairment

Because acesulfame potassium in Suito is excreted primarily unchanged by the kidneys, individuals with severe renal impairment should moderate their intake of Suito and discuss appropriate limits with their physician.

Hepatic Impairment

No specific dose adjustment of Suito is established for hepatic impairment, as neither component undergoes significant hepatic metabolism.

Elderly

Suito is generally well tolerated in elderly patients within standard ADI limits; no specific dose adjustment is required.

Suito is not used for a fixed treatment duration; it may be used on an ongoing basis as part of a regular diet or as a long-term excipient in pharmaceutical formulations, provided intake remains within the established acceptable daily intake limits for each component.

Non-nutritive Artificial Sweeteners / Sugar Substitutes (Food and Pharmaceutical Excipient Combination)

Sucralose + Acesulfame Potassium produces sweetness by both components binding to sweet taste receptors on the tongue; sucralose and acesulfame potassium together produce a synergistic sweetening effect that closely mimics the taste of sucrose without contributing significant calories or affecting blood glucose, since neither component is meaningfully metabolized by the body (see Pharmacology).

Suito is used in children as a sugar substitute, most commonly as an excipient in sugar-free pediatric oral medications and in food/beverage products, within the same weight-based acceptable daily intake (ADI) limits used for adults (5 mg/kg/day for sucralose and 15 mg/kg/day for acesulfame potassium). Use of Suito directly as a tabletop sweetener in infants and very young children is not generally recommended, and formal safety and efficacy data specifically for very young infants are limited; parents should consult a pediatrician regarding appropriate use of Suito in young children.